Eli Lilly and Company
General ticker "LLY" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $710.0B (TTM average)
Eli Lilly and Company follows the US Stock Market performance with the rate: 28.2%.
Estimated limits based on current volatility of 1.7%: low 1022.57$, high 1058.88$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-11-14, amount 1.50$ (Y0.59%)
- Total employees count: 47000 as of 2024
- US accounted for 19.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Product portfolio replenishment, Regulatory and compliance, Counterfeit products, Government pricing controls
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [691.26$, 941.41$]
- 2025-12-31 to 2026-12-31 estimated range: [710.95$, 972.78$]
Financial Metrics affecting the LLY estimates:
- Negative: with PPE of 59.9 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 28.64 > 18.64
- Negative: Shareholder equity ratio, % of 18.03 <= 18.93
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.86 > 6.04
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: Industry inventory ratio change (median), % of -0.66 <= -0.15
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Positive: Industry earnings per price (median), % of 5.67 > 4.43
Short-term LLY quotes
Long-term LLY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $28,541.40MM | $34,124.10MM | $45,042.70MM |
| Operating Expenses | $21,414.10MM | $27,666.20MM | $32,143.70MM |
| Operating Income | $7,127.30MM | $6,457.90MM | $12,899.00MM |
| Non-Operating Income | $-320.90MM | $96.70MM | $-218.60MM |
| R&D Expense | $8,099.30MM | $13,113.20MM | $14,271.00MM |
| Income(Loss) | $6,806.40MM | $6,554.60MM | $12,680.40MM |
| Taxes | $561.60MM | $1,314.20MM | $2,090.40MM |
| Profit(Loss)* | $6,244.80MM | $5,240.40MM | $10,590.00MM |
| Stockholders Equity | $10,649.80MM | $10,771.90MM | $14,192.10MM |
| Inventory | $4,309.70MM | $5,772.80MM | $7,589.20MM |
| Assets | $49,489.80MM | $64,006.30MM | $78,714.90MM |
| Operating Cash Flow | $7,585.70MM | $4,240.10MM | $8,817.90MM |
| Capital expenditure | $2,985.30MM | $7,392.10MM | $8,403.60MM |
| Investing Cash Flow | $-3,762.90MM | $-7,152.70MM | $-9,301.50MM |
| Financing Cash Flow | $-5,406.70MM | $3,495.60MM | $1,230.10MM |
| Earnings Per Share** | $6.57 | $5.83 | $11.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.